Latest Conference Articles

Thomas Powles, MD, MBBS, MRCP, discusses findings from the phase 3 EV-302 clinical trial of enfortumab vedotin-ejfv with pembrolizumab vs chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic urothelial cancer.

A trial comparing selpercatinib with cabozantinib or vandetanib led to greater benefit and favorable safety in the selpercatinib arm, supporting use of the selective RET inhibitor as first-line treatment for patients with advanced RET-mutant medullary thyroid cancer, according to interim data presented at the 2023 ESMO Congress.

Combining amivantamab, carboplatin, and pemetrexed in patients with non–small cell lung cancer and an EGFR exon 20 insertion led to improved progression-free survival, overall response rate, duration of response, and a trend toward overall survival benefit vs chemotherapy alone in the randomized phase 3 PAPILLON study.

Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.

Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.

Results of from a subgroup of patients in the phase 2 C-144-01 study with advanced mucosal melanoma showed a clinically meaningful response to lifileucel after progression on immune checkpoint inhibitors.

The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.

In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.

Findings from the FLAURA2 trial demonstrate that firstline treatment with osimertinib plus chemotherapy reduced the risk for central nervous system progression in patients with EGFR-positive non-small cell lung cancer.

Adding durvalumab to chemotherapy, followed by durvalumab and olaparib maintenance therapy improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer.

Belzutifan led to improved progression-free survival and objective response rate compared to everolimus for patients with advanced clear cell renal cell carcinoma, according to study findings.

One-year follow-up of the phase 2 study assessing the use of neoadjuvant and adjuvant cemiplimab in patients with cutaneous squamous cell carcinoma shows a promising survival benefit that has led to a wider phase 3 study.

Findings from a recent analysis of the DESTINY-Breast04 trial demonstrate improvement in efficacy when trastuzumab deruxtecan monotherapy is used for patients with HER2-low metastatic breast cancer.

Progression-free survival in the central nervous system appears to be longer with trastuzumab deruxtecan than with comparator treatment in patients with HER2-positive metastatic breast cancer and brain metastases.

Tina Cascone, MD, PhD, discusses the main findings from the phase 3 CheckMate-77T trial of a nivolumab-based regimen for the treatment of patients with stage IIA to IIIB non–small cell lung cancer.

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

Treatment with sacituzumab govitecan-hziy in the second line demonstrated responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

The addition of atezolizumab to chemotherapy improved progression-free survival in frontline advanced or recurrent endometrial carcinoma, in particular, among patients with deficient mismatch repair status.

Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.

The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.

Adding pembrolizumab to chemotherapy reduced the risk for disease recurrence, progression, complications, or death compared with chemotherapy alone in the treatment of triple-negative breast cancer.

The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.

Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.

The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.

Tarlatamab 10 mg showed responses in patients with previously treated small cell lung cancer, and no new safety signals were observed.